Abstract
We read with interest the article by Dehal, Smith and Nash (1), intitled “Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review—past, present and future” and, also congratulating them for the comprehensive review performed, we believe that, the role that hyperthermic intraperitoneal chemotherapy (HIPEC) can play in the prophylaxis of peritoneal carcinomatosis (PC) in patients with gastric cancer, should be emphasized.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
